Predicting the transition to chronic pain six months after an ED visit for acute pain. A prospective cohort study
Abstract
Background. Acute pain may transition to chronic pain, a potentially debilitating illness. Objectives. We determined how often acute pain transitions to chronic pain among ED patients and whether persistent pain 1 week after the ED visit was associated with chronic pain. Methods. An observational cohort study conducted in two EDs. We included adults with acute pain (≤10 days) if an oral opioid was prescribed. Exclusion criteria were recent opioid use or use of any analgesics regularly prior to onset of the pain. Research associates interviewed patients during the ED visit, and 1 week and 6 months later. The primary outcome, chronic pain, was defined as pain on >50% of days since ED discharge. We constructed logistic regression models to evaluate the association between persistent pain 1 week after an ED visit and chronic pain while adjusting for demographic and treatment variables. Results. During a 9-month period, we approached 733 patients for participation and enrolled 484. 450/484(93%) provided one week outcome data and 410/484(85%) provided six month outcome data. One week after the ED visit, 348/453(77%, 95%CI:73, 80%) patients reported pain in the affected area. New onset chronic pain at six months was reported by 110/408 (27%, 95%CI: 23, 31%) patients. Presence of pain one week after ED visit was associated with chronic pain (OR3.6, 95%CI:1.6,8.5). Conclusions. About one-quarter of ED patients with acute pain transition to chronic pain within six months. Persistence…
How strong is the evidence?
Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 733 participants or records.
Read the paper
Related studies
- The Matrisome: In Silico Definition and In Vivo Characterization by Proteomics of Normal and Tumor Extracellular Matrices
- The Escherichia coli MG1655 in silico metabolic genotype: Its definition, characteristics, and capabilities
- In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling
- In silico prediction of splice-altering single nucleotide variants in the human genome
- In silico clinical trials: how computer simulation will transform the biomedical industry
- In silico optimization of a guava antimicrobial peptide enables combinatorial exploration for peptide design
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.